Class II — Moderate Risk Severity Status: Ongoing Authority: FDA

GANIRELIX ACETATE

Recalling Firm / Manufacturer: Lupin Pharmaceuticals Inc. (Naples, FL, United States)
FDA Recall Number: D-0220-2026
View FDA Source
Source Authority Disclaimer: This drug recall notice is published by Questo using official enforcement reports issued by the U.S. Food & Drug Administration (FDA). It is provided for informational, academic, and clinical research purposes only. Patients should not discontinue prescribed treatments without consulting their physician or pharmacist.
Product & Identification Information
Brand, active ingredients, NDC codes, and manufacturer details
Brand / Trade Name
GANIRELIX ACETATE
Generic Name
GANIRELIX ACETATE
Active Substance(s)
Ganirelix Acetate
Administration Route
Subcutaneous
National Drug Code (NDC)
70748-274
Total Quantity Recalled
32736 vials
Official Reason for Recall
Specific hazard or quality defect cited by the FDA

According to the official FDA enforcement report:

Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.

Full Product Description
Packaging specifications and labeling details

Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syringe, 27 gauge by 1/2' needle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, United States, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-274-01

Enforcement & Regulatory Details
FDA classification, report dates, and initiation authority
Health Hazard Classification
Class II
Current Action Status
Ongoing
FDA Enforcement Report Date
December 17, 2025
Firm Initiation Date
November 13, 2025
FDA Classification Date
Dec 08, 2025
Initiation Type
Voluntary: Firm initiated
Affected Lots & Batch Numbers
Product codes, lot numbers, and expiration dates
Lot #: WB00006, Exp 12/31/2026
Distribution Information
Geographic scope of affected shipments

FL, MA, MI & OH

Safety Guidance & Actions
Standard FDA protocol for patients and healthcare providers
Patient Advisory
Check your prescription bottle or packaging against the affected lot numbers listed above. If your medication matches a recalled lot, contact your pharmacist for replacement guidance.
Healthcare Provider Guidance
Audit pharmacy stock and return affected lots to the distributor per manufacturer instructions. Notify patients where clinically indicated.

Official Source Provenance

Verified regulatory citation from U.S. FDA OpenFDA

Primary Data Source: U.S. Food & Drug Administration (FDA) OpenFDA API
Recall Number: D-0220-2026
Questo Retrieval Date: July 31, 2026 14:36 1785508608UTCC
View Official FDA Source

System Notice

Confirm Action